CeloNova BioSciences
THE CHALLENGE
Suboptimal Clinical Performance
An implanted medical device may cause various complications during and following surgery, while drug-coated balloons often fail to deliver an optimal dose of therapy. Novel surface coated solutions are needed to optimize medical device performance.
THE SOLUTION
CeloNova’s Revolutionary Surface Coated Technologies
Polyzene-F NanoCoating
Distinct from other polymers due to its ultra-purity, elasticity and ultra-high molecular weight, Polyzene-F (PzF) nanocoated implants result in safe, highly biocompatible implants.
COBRA SG Drug-Coated PTCA Balloon
The novel COBRA SG Drug-Coated PTCA Balloon with bio-active medical coating is designed to optimize non-proliferative drug delivery to address small vessel stenosis, restenosis and bifurcations.
“CeloNova aims to be an expert partner to medical device OEM’s looking for proprietary coating technologies to enhance biocompatibility, drug delivery and provide anti-inflammatory, thromboresistance and pro-healing properties.”
A History of Commercial Success
-
Cardiology - Cobra PzF Nanocoated Stent
PzF nanocoated, non drug-eluting coronary stent allows physicians to safely and effectively treat patients with short 1-month DAPT.1
-
Oncology/Radiology - Embozene™ Microspheres
PzF nanocoated spheres are designed to be virtually “invisible” to the body, reducing inflammation and unwanted tissue reaction.
Acquired by Boston Scientific in 2015. Read Press Release.
-
Oncology/Drug Elution - Tandem™ Microspheres
Embozene TANDEM® Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene®-F). They are available in a range of sizes suitable for embolic therapy.
Acquired by Boston Scientific in 2015. Read Press Release.
Shaping the Future of Quality & Safety
CeloNova is one of a handful of companies in the U.S. selected to support advancements in medical device quality and safety through partnership with the FDA’s Case for Quality Voluntary Improvement Program (CFQ VIP).
This program identifies device manufacturers that consistently produce high-quality devices to help better focus FDA resources and promote best practices to help other manufacturers raise their level of quality and safety. Through the program’s partnership, CeloNova aims to further advance quality of care in patients in the U.S.8
Partnership & Co-Development Opportunities
Now, for the first time ever, CeloNova is bringing their unique, proprietary surface coatings to the broader market, creating partnership opportunities and co-development opportunities with medical device manufacturers seeking to optimize their medical device performance.
Contact us today to learn more.